Rapid Micro Biosystems: Big Pharma Adoption Driving Growth

Rapid Micro Biosystems, Inc. posted strong FY25 revenue growth, driven by Growth Direct system placements, but remains unprofitable with a $47M net loss. RPID's growth hinges on large multi-system orders from major pharmaceutical manufacturers, with recurring revenue from consumables and services now 53% of total revenue. A premium valuation (6.4x P/S) reflects high expectations for platform adoption, but negative margins and ongoing cash burn temper near-term optimism.